- Beta-blockers associated with delayed onset and decreased progression of Huntington’s disease
- Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval
- Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
- Going boldly: First person treated in Phase 1 clinical trial by Alnylam Pharmaceuticals
- Giving Thanks to the Huntington's Disease Family Community for Advancing Research
- Self-determination on the HD journey: the role of Advanced Care Planning
- 2024 HDBuzz Prize: Beyond nerve cells – who are the other players in the HD brain?
- Face-to-face: Huntington’s disease families are heard by the FDA
- The dust has settled: Sage’s dalzanemdor won’t advance for cognitive impairment
- We are not alone, and are seeing more RED
- Huntington Study Group (HSG) Conference 2024 – Day 3
- Huntington Study Group (HSG) Conference 2024 – Day 2
- Huntington Study Group (HSG) Conference 2024 – Day 1
- 2024 HDBuzz Prize: Social Skills - The Hidden Gem in Improving Quality of Life for People with Huntington's disease?
- 2024 HDBuzz Prize: Thinking beyond therapies - it’s time to consider racial disparity in HD care and research
- Announcing the 2024 HDBuzz Prize for Young Science Writers!
- Bringing HD Treatments to Market: The Role of Regulatory Oversight
- Interruptions are encouraged
- HDBuzz needs your help
- 14 changes for a healthier brain
- Highlighting a link between brain disorders on Ataxia Awareness Day
